Predictive value of HER-2 and Topoisomerase IIα in response to primary doxorubicin in breast cancer

AimTo study the predictive role of HER-2 and Topoisomerase IIα (TOP2A) in response to primary doxorubicin.MethodsTwo hundred and thirty-two patients with operable breast cancer were treated with doxorubicin prior to surgery. ER, PgR, grade, Ki-67 and HER-2 status were prospectively assessed. HER-2 overexpression was evaluated with immunohistochemistry; positive cases were then studied for gene copy number of HER-2, TOP2A and chromosome 17 centromere by chromogenic in situ hybridisation. Clinical response was assessed by mammography. Pathological response was evaluated as the percentage of tumour replaced by changes due to chemotherapy.ResultsHER-2 amplification was associated with clinical response (p = 0.04). ER and PgR negativity, high Ki-67 and HER-2 amplification significantly correlated to pathological response (p < 0.05). Tumours with coamplification of HER-2 and TOP2A showed a higher percentage of pathological changes (p = 0.6). However, in the multivariate analysis for complete pathological response, ER negativity and high Ki-67 index were the only parameters that maintained statistical significance.ConclusionHER2 and Topoisomerase IIα amplification failed to show an association with pathological response to doxorubicin, whereas ER negativity and a high proliferation rate were predictive of complete pathological response to this regime.